版本:
中国

BRIEF-Idera Pharmaceuticals advances investigational treatment for unmet need in anti-PD-1 refractory metastatic melanoma

April 11 Idera Pharmaceuticals Inc

* Idera Pharmaceuticals advances investigational treatment – intratumoral IMO-2125 in combination with ipilimumab - for unmet need in anti-PD-1 refractory metastatic melanoma

* Idera Pharmaceuticals Inc - Enrollment has begun for phase 2 portion of trial with 8mg dose of intratumoral IMO-2125

* Idera Pharmaceuticals Inc - Phase 1 dose escalation of IMO-2125 in combination with pembrolizumab is ongoing

* Idera Pharmaceuticals - In addition to potential interim updates, expects to have overall response rate data from IMO-2125 trial available in Q1 of 2018

* Idera Pharma - To continue discussions with regulatory authorities for path to registration for IMO-2125 with ipilimumab in certain melanoma patients Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐